Catalyst Capital Advisors LLC Buys Shares of 2,475 Eli Lilly and Company $LLY

Key Points

• Catalyst Capital Advisors opened a new position in Eli Lilly, buying 2,475 shares valued at about $2.28 million in the first quarter.
• Eli Lilly continues to draw heavy institutional interest, with major holders like Vanguard, State Street, and Morgan Stanley all increasing their stakes; institutional investors now own 82.53% of the stock.
• The company remains in focus for growth and pipeline developments, including its AtaiBeckley acquisition to expand into psychedelic therapies, while analysts have mostly stayed bullish with a Moderate Buy consensus and an average price target of $1,283.64.

Catalyst Capital Advisors LLC bought a new stake in Eli Lilly and Company (NYSE:LLY - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 2,475 shares of the company's stock, valued at approximately $2,276,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. grew its position in shares of Eli Lilly and Company by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company's stock worth $88,087,193,000 after buying an additional 1,006,885 shares during the period. State Street Corp raised its position in shares of Eli Lilly and Company by 1.8% during the fourth quarter. State Street Corp now owns 35,361,916 shares of the company's stock worth $38,002,744,000 after purchasing an additional 635,358 shares during the period. Morgan Stanley lifted its holdings in shares of Eli Lilly and Company by 2.7% during the 4th quarter. Morgan Stanley now owns 15,593,019 shares of the company's stock valued at $16,757,510,000 after purchasing an additional 407,166 shares in the last quarter. Capital World Investors lifted its holdings in shares of Eli Lilly and Company by 0.4% during the 4th quarter. Capital World Investors now owns 15,031,750 shares of the company's stock valued at $16,154,619,000 after purchasing an additional 61,851 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in shares of Eli Lilly and Company by 10.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,910,505 shares of the company's stock valued at $16,024,022,000 after purchasing an additional 1,432,069 shares during the period. 82.53% of the stock is owned by institutional investors.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s acquisition of AtaiBeckley adds late-stage psychedelic assets, including BPL-003, and broadens its neuroscience pipeline. Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
• Positive Sentiment: Analysts and market commentary say the deal reinforces Big Pharma’s interest in psychedelic therapies and could strengthen Lilly’s long-term growth story beyond obesity and diabetes. AtaiBeckley acquisition highlights growing Big Pharma interest in psychedelics, says Jefferies
• Neutral Sentiment: Lilly also announced an update on an ongoing ALS study, indicating continued clinical development activity across its broader pipeline. Lilly Expands ALS Pipeline With Long-Term Safety Study for LY4256984
• Neutral Sentiment: LLY stock is being described as holding near a buy zone and key support ahead of second-quarter results, suggesting investors are also watching upcoming earnings for confirmation of the growth outlook. Eli Lilly Stock Hovers In Buy Zone, Finds Key Support Amid $3 Billion Deal
• Negative Sentiment: Some market commentary suggests the acquisition may pressure sentiment in the near term because Lilly is paying a significant price for an asset that still carries clinical and regulatory risk. This Psychedelic Pharma Stock Is Soaring 50% on Report of Eli Lilly Takeover Talks

Eli Lilly and Company Trading Up 0.8%

Shares of NYSE:LLY opened at $1,178.01 on Friday. The company's 50-day moving average price is $1,118.87 and its two-hundred day moving average price is $1,036.80. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,249.45. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The stock has a market capitalization of $1.11 trillion, a PE ratio of 41.85, a price-to-earnings-growth ratio of 1.47 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. During the same quarter last year, the firm posted $3.34 EPS. The company's quarterly revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities analysts forecast that Eli Lilly and Company will post 34.55 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company's dividend payout ratio (DPR) is 24.58%.

Analyst Upgrades and Downgrades

LLY has been the topic of several research analyst reports. Jefferies Financial Group raised their target price on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a "buy" rating in a report on Tuesday, June 9th. Citigroup increased their price objective on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a "buy" rating in a research report on Wednesday. Truist Financial raised their price objective on shares of Eli Lilly and Company from $1,281.00 to $1,370.00 and gave the stock a "buy" rating in a report on Wednesday, July 8th. Berenberg Bank upped their target price on shares of Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the stock a "hold" rating in a research note on Monday, June 22nd. Finally, UBS Group increased their target price on Eli Lilly and Company from $1,250.00 to $1,425.00 and gave the stock a "buy" rating in a report on Monday. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $1,283.64.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.